Today RS Oncology celebrates World Ovarian Cancer Day. We are hard at work with our partner, Azierta Foundation, to bring innovative treatment options for ovarian cancer patients worldwide.
Updated: Jan 22
Cambridge, Massachusetts and Madrid, Spain –September 30, 2019 – RS Oncology Ltd., Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation, announced today at the European Society for Medical Oncology (ESMO 2019) a partnership for co-development of RS Oncology’s novel therapeutic (PER-016) targeting mitochondria-based oxidative stress signaling pathways in ovarian cancer.
Azierta Contract Scientific Support Consulting, S.L. is a Science and Health consultancy firm committed to strengthening bonds between science and the business environment through the “Science to Business” concept. Azierta provides services in the field of medicinal products, Medical Devices, cosmetics, food supplements and biocides, offering complete solutions throughout products’ life cycle, from medical and regulatory support, to toxicology, manufacturing and distribution needs, market access and pharmacovigilance.
Mr. Ángel Navarro, Azierta’s CEO stated, “We are very excited to partner with RS Oncology in the development of this very exciting therapeutic. This is our first partnership and direct involvement in the development of an oncology asset through an innovative business model. We anticipate that RS Oncology's groundbreaking science will change drug development business norms and will result in novel therapies for patients.”
RS Oncology is a privately held pre-clinical biotechnology company based in Cambridge, Massachusetts. The company is currently developing a first-in-class oxidative stress modulator (PER-016) scheduled to enter Phase I clinical development in 1H20. This novel MOA targeted treatment approach is expected to have broad efficacy in various disease states of oxidative stress dysregulation. “This innovative partnership will allow us to expand into additional indications currently outside of our corporate strategy. This will ultimately speed up the process of reaching as many patients as possible sooner than anticipated with our exciting and potentially life-changing therapy,” stated Jarrett Duncan, CEO of RS Oncology.
Media Contacts: RS Oncology Jarrett Duncan, CEO George Naumov, COO and Head of Business Development One Broadway, 14th floor Cambridge, MA 02142 email@example.com Email: firstname.lastname@example.org; email@example.com
Azierta Contract Scientific Support Consulting, S.L. and Azierta Foundation Ángel Navarro, Azierta’s CEO Eduardo Rodenas, VP Azierta Foundation Via de las Dos Castillas 33 Edificio 7 28224 Pozuelo de Alarcon (Madrid) Tel. 91 277 1076 firstname.lastname@example.org